The companies launched Onduo, a joint venture focused on developing solutions to assist patients with Type 2 diabetes.
Sanofi and Verily Life Sciences announced on Sept. 12, 2016 the launch of Onduo. Onduo, a joint venture created through Sanofi and Verily’s diabetes-focused collaboration, is designed to help patients with diabetes through the development of solutions that combine devices, software, medicine, and professional care. The companies appointed Joshua Riff, MD, MBA, Onduo’s chief executive officer, a former senior vice-president of UnitedHealth Group. “We want to develop solutions that allow people living with diabetes to focus on the things they love and enjoy in life by providing tools to make dealing with their diabetes less burdensome,” Riff said in a statement.
Onduo will initially focus on Type 2 diabetes, specifically focusing on improved medication management, and other daily decisions to help patients better manage their diabetes. Eventually Onduo says it will expand to include Type 1 diabetes and eventually, to people at risk of developing diabetes. Sutter Health of Northern California and Allegheny Health Network of western Pennsylvania are among the first healthcare networks to collaborate with Verily and Onduo to test the Onduo platform with healthcare professionals and people with Type 2 diabetes in a clinical-care setting.
Source: Sanofi
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.